.Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AL12_IndacaterolGlycopyrroniumBromide.IndacaterolGlycopyrroniumBromide .Pharmacolibrary.Drugs.R_RespiratorySystem.R03A_AdrenergicsInhalants.R03AL12_IndacaterolGlycopyrroniumBromide.IndacaterolGlycopyrroniumBromide| name: | IndacaterolGlycopyrroniumBromideAndMometasone |
| ATC code: | R03AL12 | route: | inhalation |
| n-compartments | 1 |
Indacaterol, glycopyrronium bromide, and mometasone is a fixed-dose combination inhalation medication used for maintenance treatment of asthma in adults, containing an ultra-long-acting beta2-agonist (indacaterol), a long-acting muscarinic antagonist (glycopyrronium bromide), and an inhaled corticosteroid (mometasone furoate). It is approved for use in several countries for regular treatment of asthma where combination therapy is appropriate.
Pharmacokinetic parameters for the fixed-dose triple combination (indacaterol, glycopyrronium, and mometasone furoate) in adult asthmatic patients, following once-daily inhaled administration via Breezhaler.
Bartels, C, et al., & Vaidya, S (2021). Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler. European journal of drug metabolism and pharmacokinetics 46(4) 487–504. DOI:10.1007/s13318-021-00689-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/34024035
Inoue, S, et al., & Furihata, K (2021). Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects. BMC pulmonary medicine 21(1) 18–None. DOI:10.1186/s12890-020-01382-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33413291